Jinwu Financial News | China Biopharmaceutical (01177) announced that the KRAS G12C inhibitor “garsorasib (D-1553 tablets)” jointly developed by the Group has announced the latest results of the Phase II clinical trial (NCT05383898) at the 2024 American Cancer Association Annual Meeting (AACR) for non-small cell lung cancer (NSCLC) patients with KRAS G12C mutations.
The results of this study showed that in patients with locally advanced or metastatic NSCLC after anti-PD- (L) 1 treatment and platinum-containing chemotherapy, the objective remission rate (ORR) of garsorasib was 50%, the disease control rate (DCR) was 89%, the median duration of remission (DOR) was 12.8 months, and the median progression-free survival (PFS) was 7.6 months.
KRAS mutations are widely found in many high-fatality cancers. Among them, KRASG12C is a specific KRAS mutation, accounting for about 44% of all KRAS mutations. KRASG12C mutations are common in lung cancer, colorectal cancer, pancreatic cancer, and bile duct cancer. Frost & Sullivan data shows that from 2016 to 2020, the number of cases of major KRASG12C mutant cancers in China increased from 38,000 to 43,000, and is expected to reach 58,000 in 2030. The potential market is huge.